logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

bluebird bio Announces a European Conditional Approval of Its Gene Therapy ZYNTEGLO™ for Transfusion-Dependent β-Thalassemia  

Zynteglo™ from bluebird bio Gets European Conditional Approval European marketing authorization for Zynteglo follows the fastest assessment of an advanced therapy medicinal product ( ATMP ) as part of the European Medicines Agency’s Priority Medicines ( PRIME ) program. Zynteglo...

Read More

June 4, 2019

0

Jazz Pharmaceuticals has good, not bad news

In today’s news  Jazz Pharmaceuticals (JAZZ) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for the approval of solriamfetol.  Solriamfetol  is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for treatment of  excessive daytime...

Read More

November 9, 2018

0

Must Read News. See Also: A New Immunotherapy Combination by Incyte and AstraZeneca

Amgen (AMGN) and   Kirin Holdings (Kirin) announced an agreement upon, which Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen. The...

Read More

October 31, 2017

0

What the Aimmune and Nestlé Health Science agreement tells us

Aimmune Therapeutics (AIMT) has news. A lot of it is from a successful phase 3 trial for its peanut allergy drug as well as other news that boosts our conviction that this product is, indeed, important and has a good...

Read More

November 14, 2018

0

Loxo Oncology product Vitrakvi® has been granted FDA approval. The real meaning of the approval

As we expected in our posting yesterday under Today’s Highlights, the U.S. Food and Drug Administration (FDA) approved Loxo Oncology's (LOX O )   Vitrakvi ®  (larotrectinib) , the first oral TRK inhibitor for adult and pediatric patients with solid tumors...

Read More

November 27, 2018

0

Vertex: Offering proof of leadership in treating Cystic Fibrosis

Vertex Pharmaceuticals’ triple combination, which added the corrector VX-659 to the tezacaftor and ivacaftor combination, resulted in statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV 1 ) in two Phase 3 studies...

Read More

November 29, 2018

0

Nektar Therapeutics: Speeding Its Flight Towards the Moon

Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s fundamentals from reported finances, to reported products’ results, etc.,  Cash and investments in marketable securities at September 30, 2017, were  $412.2 million  as compared to $389.1...

Read More

November 8, 2017

0

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression After 2 Years of Treatment

Good News about Novartis' Cosentyx ® for Psoriatic Arthritis Novartis ( NVS )   has good news for Cosentyx ® .  Data emerging out 0f the FUTURE 5 clinical trial on patients with psoriatic arthritis  (PsA)  showed that there was...

Read More

June 12, 2019

0

bluebird bio: Why This Firm's Stock Gained $6.37 Yesterday

Why has bluebird bio Been Hammered in the Market Recently? Investors should be asking why bluebird bio ( BLUE ) has been hammered in the market recently before asking why the stock gained $6.37 in trading yesterday. Why was it...

Read More

June 14, 2019

0

Pfizer to Acquire Array Biopharma at $48 a Share

Pfizer to Acquire Array Pfizer ( PFE ) announced that it has agreed to acquire Array Biopharma ( ARRY ) in a deal valued at $11.4 billion .  The Terms of the Agreement Under the terms of the agreement ,...

Read More

June 17, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 59
  • 60
  • 61
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy